Oncotarget

Research Papers:

High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients

Li Peng, Xiao-Qing Yuan, Chao-Yang Zhang, Fei Ye, Hui-Fang Zhou, Wen-Ling Li, Zhao-Yang Liu, Ya-Qin Zhang, Xi Pan and Guan-Cheng Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:34387-34397. https://doi.org/10.18632/oncotarget.16166

Metrics: PDF 1912 views  |   HTML 1982 views  |   ?  


Abstract

Li Peng1,2,3, Xiao-Qing Yuan4,5, Chao-Yang Zhang1,2,3, Fei Ye6, Hui-Fang Zhou7, Wen-Ling Li1,2,3, Zhao-Yang Liu1,2,3, Ya-Qin Zhang1,2,3, Xi Pan1,2,3,8, Guan-Cheng Li1,2,3

1Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha 410078, P.R. China

2Key Laboratory of Carcinogenesis and Cancer Invasion of Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha 410078, P.R. China

3Cancer Research Institute, Central South University, Changsha 410078, P.R. China

4Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P.R. China

5Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P.R. China

6Department of Cardiology, the Third Xiangya Hospital, Central South University, Changsha 410100, P.R. China

7Department of Physiology, Changsha Health Vocational College, Changsha 410100, P.R. China

8Department of Oncology, the third Xiangya Hospital, Central South University, Changsha 410013, P.R. China

Correspondence to:

Guan-Cheng Li, email: ligc61@csu.edu.cn

Xiao-Qing Yuan, email: yuanxq@csu.edu.cn

Keywords: transforming growth factor beta 1, hepatocellular carcinoma, prognosis, overall survival, meta-analysis

Received: December 28, 2016     Accepted: March 04, 2017     Published: March 13, 2017

ABSTRACT

Transforming growth factor beta (TGF-β) promotes the pathogenesis of hepatocellular carcinoma (HCC). We evaluated the associations between TGF-β1 expression and clinicopathological parameters in HCC patients from The Cancer Genome Atlas (TCGA), as well as the prognostic power of TGF-β1 expression. Eligible studies were retrieved from several databases, and effects (hazard ratios (HRs) with 95% confidence intervals (CIs)) for overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), metastasis-free survival (MFS), and progression-free survival (PFS) were pooled to assess the prognostic ability of TGF-β1 expression in HCC patients. Twelve qualified articles and our TCGA data comprising 2,021 HCC patients were incorporated. In the TCGA analysis, HCC patients with higher TGF-β1 expression presented a shorter OS than those with lower TGF-β1 expression (HR = 1.42, p < 0.05). In the meta-analysis, univariate analyses showed that HCC patients with higher TGF-β1 expression had a shorter OS (pooling HR = 1.71, p < 0.01) and DFS/RFS/MFS/PFS (pooling HR = 1.60, p < 0.01) than those with lower TGF-β1 expression. In conclusion, our results suggested that high TGF-β1 expression promotes a poor prognosis in HCC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16166